Articles tagged with: ASH 2012 Meeting

News»

[ by | Dec 8, 2012 6:17 am | 4 Comments ]
Tips For Making Sense Of The Research Results Presented At This Year’s ASH Annual Meeting

Today marks the first day of presentations and poster sessions at the 2012 American Society of Hematology (ASH) annual meeting.

The meeting, which is being held in Atlanta this year, will provide the multiple myeloma community with a veritable deluge of new research about existing myeloma treatments as well as therapies that are still under development.

As was the case with previous ASH annual meetings, The Myeloma Beacon will be covering this year’s meeting in detail.  Beacon readers can expect regular updates as the meeting proceeds, and additional, in-depth articles …

Read the full story »

News»

[ by | Nov 30, 2012 3:39 pm | 5 Comments ]
The Myeloma Beacon To Report The Latest Research From The Upcoming American Society Of Hematology Annual Meeting (ASH 2012)

The American Society of Hematology (ASH) will kick off its 54th annual meeting next Saturday, December 8. This year’s meeting will run through Tuesday, December 11 and will be held in Atlanta.

Similar to past years, over 20,000 people are expected to attend the meeting to listen to experts from around the world discuss current research regarding the biology, diagnosis, treatment, and progression of various blood diseases, including multiple myeloma.

The ASH meeting, along with the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings, are …

Read the full story »

News»

[ by | Nov 19, 2012 1:03 pm | 5 Comments ]
New Multiple Myeloma Treatments On The Horizon (ASH 2012)

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clinical trials involving a number of potential new drugs under development for the treatment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to …

Read the full story »